Shanghai Kehua Bio-Engineering Co (002022) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Aug 8, 2026
From 1 valuation models · updated today
Share price +11.6% over the past month.
Below-average quality, and screening another 85% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥0.9800). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (¥0.5200 to ¥0.9800) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.
How to read this chart
60‑month range ¥4.58 – ¥17.72 · fair‑value band ¥0.5200 – ¥0.9800 · the ¥5.29 price screens above the ¥0.7800 fair value. Dashed = 300-day average. As of Aug 8, 2026.
Analysis
Shanghai Kehua Bio-Engineering Co (002022) currently trades at ¥5.29, while our model-based Fair Value estimate is ¥0.7800, implying the stock looks roughly 85.3% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Shanghai Kehua Bio-Engineering Co generated revenue of 1.6B CNY at a net margin of -44.1%. Revenue grew 1.9% year over year. It earns a return on equity of -25.0%. The balance sheet holds a net cash position of 455M CNY. Fundamentals as of Aug 8, 2026
Our scenario range runs from ¥0.5200 (bear case) to ¥0.9800 (bull case); at ¥5.29, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -85%, 002022 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally.
Full company description
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. Further, it provides instrument products, including biochemical diagnostics, immunological diagnostics, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry, advancing towards automation, digitization, and intelligence. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Kehua Bio-Engineering Co reported revenue of ¥1.6B in FY2025 versus ¥4.9B in FY2021, a compound −23.7%/yr. Reported net income was −¥732M in FY2025.
002022 screens 85% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Shanghai Kehua Bio-Engineering Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Kehua Bio-Engineering Co (002022) overvalued or undervalued?
What is the fair value of 002022?
What is the quality score of 002022?
What is the revenue of Shanghai Kehua Bio-Engineering Co (002022)?
What is the net profit margin of 002022?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Kehua Bio-Engineering Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.